ImmunoGen (DB:IMU) - Hisse Senedi Fiyatı, Haberler ve Analizler

IMU Stoklara Genel Bakış

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. Daha fazla detay

IMU temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	6/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 2.6% daha düşük bir oranda işlem görüyor

Kazançların yılda 45.91% oranında artması öngörülüyor

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Hissedarlar geçen yıl sulandırıldı

ImmunoGen, Inc. Rakipler

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€827.2m

Heidelberg Pharma

XTRA:HPHA

€103.9m

SCHOTT Pharma KGaA

XTRA:1SXP

€4.0b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti ImmunoGen
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$28.74
52 Haftanın En Yüksek Seviyesi	US$29.00
52 Haftanın En Düşük Seviyesi	US$3.36
Beta	1.17
11 Aylık Değişim	7.04%
3 Aylık Değişim	110.09%
1 Yıllık Değişim	615.55%
33 Yıllık Değişim	226.59%
5 Yıllık Değişim	482.96%
Halka arzdan bu yana değişim	1,149.57%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	IMU	DE Biotechs	DE Pazar
7D	6.8%	-0.7%	0.2%
1Y	615.5%	-17.2%	8.5%

Getiri vs. Endüstri: IMU geçen yıl % -17.2 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: IMU geçen yıl % 8.5 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is IMU's price volatile compared to industry and market?
IMU volatility
IMU Average Weekly Movement	25.0%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

İstikrarlı Hisse Senedi Fiyatı: IMU hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: IMU 'nin haftalık oynaklığı ( 25% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1980	277	Mark Enyedy	www.immunogen.com

ImmunoGen, Inc. Temel Bilgiler Özeti

ImmunoGen'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IMU temel i̇stati̇sti̇kler
Piyasa değeri	€7.76b
Kazançlar(TTM)	-€68.27m
Gelir(TTM)	€267.08m

29.1x

P/S Oranı

-113.7x

F/K Oranı

IMU aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IMU gelir tablosu (TTM)
Gelir	US$287.61m
Gelir Maliyeti	US$211.62m
Brüt Kâr	US$76.00m
Diğer Giderler	US$149.52m
Kazançlar	-US$73.52m

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.27
Brüt Marj	26.42%
Net Kâr Marjı	-25.56%
Borç/Özkaynak Oranı	12.8%

IMU uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

IMU Stoklara Genel Bakış

Ödüller

Risk Analizi

ImmunoGen, Inc. Rakipler

XTRA:BIO3

€1.4b

XTRA:FYB

€827.2m

XTRA:HPHA

€103.9m

XTRA:1SXP

€4.0b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Forecast breakeven date pushed back to 2024

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Forecast breakeven date pushed back to 2024

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

Insider recently sold €1.4m worth of stock

Forecast breakeven date moved forward to 2023

Third quarter 2023 earnings released: EPS: US$0.11 (vs US$0.31 loss in 3Q 2022)

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

New major risk - Share price stability

Insider recently sold €1.2m worth of stock

ImmunoGen, Inc. Announces Executive Changes

President recently sold €15m worth of stock

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

Forecast breakeven date moved forward to 2024

ImmunoGen, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.24 loss in 2Q 2022)

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.095 loss in 1Q 2022)

No longer forecast to breakeven

Forecast to breakeven in 2025

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.18 loss in 3Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

First quarter 2022 earnings released: US$0.095 loss per share (vs US$0.17 loss in 1Q 2021)

ImmunoGen, Inc. Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ImmunoGen, Inc. Appoint Executives

Forecast to breakeven in 2024

ImmunoGen Appoints Mimi Huizinga as Senior Vice President and Head of Medical Affairs

Forecast to breakeven in 2024

ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 2Q 2020)

ImmunoGen, Inc. Announces Mature Data from Forward II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin in Recurrent Ovarian Cancer, Regardless of Platinum Status

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.17 loss in 1Q 2020)

ImmunoGen, Inc. Provides Revenue Guidance for the Year of 2021

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.70 loss in FY 2019)

Hissedar Getirileri

Fiyat Oynaklığı